In 2022, the launch of China's innovative drugs will accelerate again

On January 3, Hengrui Medicine issued an announcement stating that the State Drug Administration has recently approved the listing of two innovative drugs from Hengrui Medicine
.
They are Dulceli isethionate tablets and Henggligliflozin proline tablets, both of which are class 1 new drugs
.
Among them, Dalceli is the first Chinese original CDK4/6 inhibitor.
The approved indication is the combination of fulvestrant for hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative.
Treatment of recurrent or metastatic breast cancer that has progressed after endocrine therapy
.
In addition, Henggliflozin is currently the first domestically-made innovative SGLT2 inhibitor approved to improve blood glucose control in adults with type 2 diabetes
.
With the successive approvals of two new drugs, Hengrui Medicine has launched 10 innovative drugs
.
The industry believes that Hengrui Pharmaceutical’s continuous breakthroughs in innovative drugs are actually the epitome of the continuous development of the domestic innovative drug industry.
In recent years, under the intensive introduction of a series of policies that favor the development of innovative drugs, a large number of pharmaceutical companies have begun.
Vigorously develop innovative drugs, and innovative results have begun to show up
.
For example, BeiGene has also gained a lot in innovation in recent years
.
Currently, it has promoted 11 drug candidates to enter the clinic.
Among them, BTK inhibitor zebutinib, PD-1 antibody drug tislelizumab, and PARP inhibitor pamidarib have been launched on the market
.
It’s worth mentioning that, according to the previous company’s prospectus, as of November 4, 2021, in addition to commercialized drugs and declared drug candidates, the company has 36 drug candidates in the clinical research stage and are developing more than 50 preclinical research projects
.
It is worth mentioning that under the efforts of major pharmaceutical companies, in 2021, the State Food and Drug Administration has approved 81 new drugs for the market, which is a record high compared with the 48 new drugs in 2020
.
In addition to the substantial increase in the number, it is also very rich in the field of treatment.
Approved drugs mainly involve drugs for diseases such as tumors, autoimmune system, viruses, and infections
.
It is worth mentioning that, in addition to biopharmaceuticals, many new Chinese medicines are included in the new drugs approved for marketing.

.
From an overall point of view, it is clear that the country has ushered in a major trend of drug innovation
.
Analysts believe that, driven by policies, superimposed on the science and technology innovation board, registration system, etc.
, innovative drug track capital will continue to flock, which will accelerate the financing of innovative drug companies and accelerate the harvesting period of domestic innovative drugs
.
Especially on December 30, 2021, 8 departments including the State Food and Drug Administration jointly issued the "Fourteenth Five-Year Plan for National Drug Safety and Promotion of High-quality Development" (hereinafter referred to as the "Plan"), which clarified China’s "Fourteenth Five-Year Plan".
"During the period, the main development goals of drug safety and promotion of high-quality development, and the formulation of 10 main tasks, the industry believes that more and more innovative products will continue to be approved for marketing in the country in the next few years
.
However, it should be noted that although the number of innovative drugs approved has increased rapidly in the past two years, there are not many First-in-class new drugs approved in China; the varieties are mainly concentrated in anti-tumor drugs and anti-tumor drugs.
virus and anti-infectives and analgesics and so on
.
Therefore, in the future, pharmaceutical companies also need to study new targets, new mechanisms, and new indications, and continue to increase R&D investment
.